Section 122DAB(3) in The Drugs and Cosmetics Rules, 1945
(3)[ In the case of clinical trial related death of the subject, his/her nominee(s) would be entitled for financial compensation, as per tHe order of the Licensing Authority defined under clause (b) of rule 21, and the financial compensation will be over and above any expenses incurred on the medical management of such subject.
